Cargando…

HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC

Currently, non-small cell lung carcinoma (NSCLC) is a major worldwide health problem. Meanwhile accumulating evidence indicates that histone deacetylase (HDAC) activation could induce PD-L1 expression in various types of cancer, especially in myeloma and B-cell lymphomas. Therefore, we hypothesized...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiaomei, Wang, Yuxi, Zhang, Rong, Jin, Ting, Qu, Liangliang, Jin, Qianwen, Zheng, Jiasu, Sun, Jiaqi, Wu, Ziqing, Wang, Linxi, Liu, Tianxu, Zhang, Yinxu, Meng, Xiao, Wang, Ying, Wei, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186423/ https://www.ncbi.nlm.nih.gov/pubmed/32373519 http://dx.doi.org/10.3389/fonc.2020.00485

Ejemplares similares

PIG3 promotes NSCLC cell mitotic progression and is associated with poor prognosis of NSCLC patients
por: Li, Ming, et al.
Publicado: (2017)

Tumor‐associated macrophages (TAMs)‐derived osteopontin (OPN) upregulates PD‐L1 expression and predicts poor prognosis in non‐small cell lung cancer (NSCLC)
por: Li, Yue, et al.
Publicado: (2021)

Reduced Expression of PTPRD Correlates with Poor Prognosis in Gastric Adenocarcinoma
por: Wang, Dandan, et al.
Publicado: (2014)

High HDAC5 expression correlates with a poor prognosis and the tumor immune microenvironment in gastric cancer
por: Yuan, Li, et al.
Publicado: (2022)

Overexpression of HDAC9 is associated with poor prognosis and tumor progression of breast cancer in Chinese females
por: Huang, Yixiang, et al.
Publicado: (2018)

Decreased Preoperative Estimated Glomerular Filtration Rate Was Related With Poor Prognosis of NSCLC Patients
por: Jia, Wenqiao, et al.
Publicado: (2020)

Th1(high) in tumor microenvironment is an indicator of poor prognosis for patients with NSCLC
por: Jian, Huang, et al.
Publicado: (2017)

CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients
por: Tan, Li-Ming, et al.
Publicado: (2019)

PD-L2 based immune signature confers poor prognosis in HNSCC
por: Qiao, Yu, et al.
Publicado: (2021)

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
por: Schmidt, Lars Henning, et al.
Publicado: (2015)

Correction: Th1(high) in tumor microenvironment is an indicator of poor prognosis for patients with NSCLC
por: Jian, Huang, et al.
Publicado: (2017)

Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma
por: Zeng, Zhen, et al.
Publicado: (2011)

TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors
por: He, Jun-chuang, et al.
Publicado: (2016)

Regional emphysema score is associated with tumor location and poor prognosis in completely resected NSCLC patients
por: Heo, Jung Won, et al.
Publicado: (2020)

CDK5 neutralizes the tumor suppressing effect of BIN1 via mediating phosphorylation of c-MYC at Ser-62 site in NSCLC
por: Zhang, Xiangyu, et al.
Publicado: (2019)

Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC)
por: Tang, Zhiyuan, et al.
Publicado: (2016)

BDNF expression in GISTs predicts poor prognosis when associated with PD-L1 positive tumor-infiltrating lymphocytes
por: Tian, Guang-Ang, et al.
Publicado: (2021)

Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer
por: Jiao, Feng, et al.
Publicado: (2016)

Enhanced osteopontin splicing regulated by RUNX2 is HDAC-dependent and induces invasive phenotypes in NSCLC cells
por: Huang, Jing, et al.
Publicado: (2019)

Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
por: Ma, Long, et al.
Publicado: (2021)

HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression
por: Li, Xiaolei, et al.
Publicado: (2021)

PD-L1 combined with HDAC9 is a useful prognostic predictor in hepatocellular carcinoma
por: Yang, Zhao, et al.
Publicado: (2021)

PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance
por: Zhang, Yan, et al.
Publicado: (2017)

High HDAC9 is associated with poor prognosis and promotes malignant progression in pancreatic ductal adenocarcinoma
por: Li, He, et al.
Publicado: (2020)

Potential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors
por: Wang, Yuqian, et al.
Publicado: (2023)

Overexpression of POLA2 in hepatocellular carcinoma is involved in immune infiltration and predicts a poor prognosis
por: Liu, Long, et al.
Publicado: (2023)

Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma
por: Que, Yi, et al.
Publicado: (2021)

An independent poor-prognosis subtype of hepatocellular carcinoma based on the tumor microenvironment
por: Wang, Junfeng, et al.
Publicado: (2021)

Anti–PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status
por: Matsubara, Taichi, et al.
Publicado: (2021)

Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma
por: Liu, Li-Li, et al.
Publicado: (2020)

Comprehensive Analysis of HDAC Family Identifies HDAC1 as a Prognostic and Immune Infiltration Indicator and HDAC1-Related Signature for Prognosis in Glioma
por: Fan, Yuxiang, et al.
Publicado: (2021)

Hyperglycemia is a strong predictor of poor prognosis in COVID-19
por: Liu, Sheng-ping, et al.
Publicado: (2020)

Long noncoding RNA AFAP1-AS1 is upregulated in NSCLC and associated with lymph node metastasis and poor prognosis
por: Leng, Xuechun, et al.
Publicado: (2018)

Overexpressed transferrin receptor implied poor prognosis and relapse in gastrointestinal stromal tumors
por: Zhuang, Chun, et al.
Publicado: (2023)

Upregulation of PD-L1 predicts poor prognosis and is associated with miR-191-5p dysregulation in colon adenocarcinoma
por: Chen, Xiao-Yu, et al.
Publicado: (2018)

OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC
por: Hao, Yanzhang, et al.
Publicado: (2014)

Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer
por: Qing, Yi, et al.
Publicado: (2015)

Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition
por: Han, Rui, et al.
Publicado: (2023)

Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma
por: Tang, Yanyan, et al.
Publicado: (2017)

Poor prognosis of NSCLC located in lower lobe is partly mediated by lower frequency of EGFR mutations
por: Lee, Hyun Woo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4keeabktgsbg8ma58f2ki1uhb6